NovaGo Therapeutics closes USD 30M Series B
Analysis based on 9 articles · First reported Jul 20, 2026 · Last updated Sep 02, 2026
The financing provides NovaGo with capital to advance its lead candidate into a pivotal proof-of-concept study, potentially accelerating development of a first-in-class regenerative therapy for spinal cord injury. For investors, the participation of established biopharma Neurimmune and venture fund Pureos signals confidence in the science, likely positively impacting sentiment for NovaGo and its backers.
NovaGo Therapeutics AG, a clinical-stage biotechnology company developing anti-Nogo-A biologics for central nervous system diseases, announced the successful completion of a CHF 24 million (USD 30 million) Series B financing round. The round was led by Neurimmune and Pureos Bioventures, with participation from existing and new investors. The equity financing is complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life. Proceeds will be used to advance NovaGo's lead program into a proof-of-concept study in patients with acute spinal cord injury, a randomized, double-blind trial enrolling 120 patients across sites in Germany, Spain, and Switzerland. NovaGo's approach targets Nogo-A, a protein that inhibits nerve fiber regeneration, aiming to enable functional recovery. The company highlighted promising Phase 1 results with NG004 and the high unmet medical need in spinal cord injury, where no approved regenerative treatments exist.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard